

Alaide Chieffo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4074118/publications.pdf>

Version: 2024-02-01

394
papers

30,697
citations

7568

77
h-index

5539

163
g-index

406
all docs

406
docs citations

406
times ranked

18331
citing authors

#	ARTICLE	IF	CITATIONS
1	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	3.2	5
2	Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions. Cardiovascular Revascularization Medicine, 2022, 35, 66-73.	0.8	3
3	Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 881-891.	4.0	6
4	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization. , 2022, 1, 100016.		2
5	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. Journal of the American Heart Association, 2022, 11, e022320.	3.7	5
6	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	1.6	4
7	Anticoagulation for Percutaneous Ventricular Assist Device-Supported Cardiogenic Shock. Journal of the American College of Cardiology, 2022, 79, 1949-1962.	2.8	36
8	STEMIs and a Closer Look at MINOCA During the COVID-19 Pandemic. , 2022, , 100372.		1
9	Transcatheter Aortic Bioprosthesis Durability: A Single-Center Experience. Cardiovascular Revascularization Medicine, 2022, 43, 1-6.	0.8	3
10	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	2.8	25
11	The impact of chronic kidney disease severity on clinical outcomes after current generation drug-eluting stent implantation for left main distal bifurcation lesions: the Milan and New-Tokyo registry. Scandinavian Cardiovascular Journal, 2022, 56, 236-242.	1.2	0
12	Clinical outcomes of double stent strategy for unprotected left main distal bifurcation lesions using current generation drug eluting stent comparing to early generation drug eluting stent; The Milan and New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2021, 97, E198-E208.	1.7	2
13	Accuracy of the PARIS score and PCI complexity to predict ischemic events in patients treated with very thin stents in unprotected left main or coronary bifurcations. Catheterization and Cardiovascular Interventions, 2021, 97, E227-E236.	1.7	6
14	T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models. Cardiovascular Revascularization Medicine, 2021, 24, 11-17.	0.8	5
15	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	1.7	3
16	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	1.7	8
17	Prevalence, predictors, and outcomes of patient prosthesis mismatch in women undergoing <scp>TAVI</scp> for severe aortic stenosis: Insights from the <scp>WIN-TAVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 97, 516-526.	1.7	17
18	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2021, 42, 1289-1367.	2.2	3,048

#	ARTICLE	IF	CITATIONS
19	Unplanned Percutaneous Coronary Revascularization After TAVR. JACC: Cardiovascular Interventions, 2021, 14, 198-207.	2.9	30
20	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal, 2021, 42, 967-984.	2.2	136
21	Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet, The, 2021, 397, 199-207.	13.7	164
22	Performing elective cardiac invasive procedures during the COVID-19 outbreak: a position statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention, 2021, 16, 1177-1186.	3.2	9
23	Gender Issues in Italian Catheterization Laboratories: The Genderâ€CATH Study. Journal of the American Heart Association, 2021, 10, e017537.	3.7	4
24	Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club. EuroIntervention, 2021, 16, 1307-1317.	3.2	147
25	The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet, The, 2021, 397, 2385-2438.	13.7	530
26	RENASCENT III: First in Human Evaluation of the Novel Thin Strut MAGNITUDE Sirolimus-Eluting Ultra-High Molecular Weight MAGNITUDE Bioresorbable Scaffold: 9-Month Imaging and 2-Year Clinical Results. Circulation: Cardiovascular Interventions, 2021, 14, e010013.	3.9	1
27	The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN). European Heart Journal, 2021, 42, 3829-3839.	2.2	119
28	Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 570-583.	1.0	38
29	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	1.7	7
30	Device-related complications after Impella mechanical circulatory support implantation: an IMP-IT observational multicentre registry substudy. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 999-1006.	1.0	16
31	The importance of achieving sex- and gender-based equity in clinical trials: a call to action. European Heart Journal, 2021, 42, 2990-2994.	2.2	19
32	The importance of proximal optimization technique with intravascular imaging guided for stenting unprotected left main distal bifurcation lesions: The Milan and Newâ€Tokyo registry. Catheterization and Cardiovascular Interventions, 2021, 98, E814-E822.	1.7	4
33	Clinical impact of bifurcation angle change between diastole and systole in complex stenting for left main distal bifurcation: The Milan and Newâ€Tokyo (MITO) Registry. Catheterization and Cardiovascular Interventions, 2021, 98, E24-E34.	1.7	3
34	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. Journal of the American College of Cardiology, 2021, 78, 1968-1986.	2.8	11
35	Post-stenting optimisation techniques in bifurcation percutaneous coronary interventions: much remains to be explored. EuroIntervention, 2021, 17, e869-e871.	3.2	0
36	Safety and efficacy of polymerâ€free biolimusâ€eluting stents versus ultrathin stents in unprotected left main or coronary bifurcation: A propensity score analysis from the RAIN and CHANCE registries. Catheterization and Cardiovascular Interventions, 2020, 95, 522-529.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Comparison between functional and intravascular imaging approaches guiding percutaneous coronary intervention: A network meta-analysis of randomized and propensity matching studies. Catheterization and Cardiovascular Interventions, 2020, 95, 1259-1266.	1.7	15
38	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, 100-111.	1.7	16
39	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
40	Impact of structural features of very thin stents implanted in unprotected left main or coronary bifurcations on clinical outcomes. Catheterization and Cardiovascular Interventions, 2020, 96, 1-9.	1.7	15
41	Edwards SAPIEN Versus Medtronic Aortic Bioprosthesis in Women Undergoing Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2020, 125, 441-448.	1.6	9
42	Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. American Journal of Cardiology, 2020, 125, 491-499.	1.6	10
43	Percutaneous Transjugular Tricuspid Valve-In-Valve Implantation for Degenerated Surgical Bioprosthetic Valve. Cardiovascular Revascularization Medicine, 2020, 21, 808-809.	0.8	0
44	Impella RP support in refractory right ventricular failure complicating acute myocardial infarction with unsuccessful right coronary artery revascularization. International Journal of Cardiology, 2020, 302, 135-137.	1.7	17
45	Impact of the metal-to-artery ratio on clinical outcomes in left main and nonleft main bifurcation: insights the RAIN-CARDIOGROUP VII study (very thin stents for patients with left main or bifurcation) Tj ETQq1 1 0.784314 rgBT /Overl	1.7	15
46	Comparison of bioresorbable vs durable polymer drug-eluting stents in unprotected left main (from) Tj ETQq0 0 0 rgBT /Overl 10 Tf 5	1.7	5
47	Active Protection of High-Risk Small Side Branches in Bifurcation Interventions. JACC: Cardiovascular Interventions, 2020, 13, 1123-1125.	2.9	1
48	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. European Heart Journal, 2020, 41, 1839-1851.	2.2	106
49	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. Catheterization and Cardiovascular Interventions, 2020, 96, 1067-1079.	1.7	57
50	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	3.9	21
51	Italian Society of Interventional Cardiology (GISE) position paper for Cath lab-specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID -19. Catheterization and Cardiovascular Interventions, 2020, 96, 839-843.	1.7	30
52	Revascularization Options for Females With Multivessel Coronary Artery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1009-1010.	2.9	12
53	Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researchH in womEn all) Tj ETQq1 1 0.784314 rgBT /Overl	2.7	12
54	An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal, 2020, 41, 3504-3520.	2.2	385

#	ARTICLE	IF	CITATIONS
55	Impact of Kissing Balloon in Patients Treated With Ultrathin Stents for Left Main Lesions and Bifurcations. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008325.	3.9	39
56	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WIN-TAVI) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 198-207.	1.7	13
57	ST-Elevation Myocardial Infarction in Patients With COVID-19. <i>Circulation</i> , 2020, 141, 2113-2116.	1.6	376
58	Observational multicentre registry of patients treated with IMPella mechanical circulatory support device in Italy: the IMP-IT registry. <i>EuroIntervention</i> , 2020, 15, e1343-e1350.	3.2	51
59	First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial. <i>EuroIntervention</i> , 2020, 16, e133-e140.	3.2	8
60	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>EuroIntervention</i> , 2020, 16, 233-246.	3.2	19
61	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	3.9	6
62	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1704-1711.	3.4	2
63	Interatrial Septal Tear After Patent Foramen Ovale Closure With the NobleStitch Device. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, e139-e140.	2.9	13
64	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. <i>Lancet</i> , 2019, 394, 1325-1334.	13.7	406
65	Clinical expert consensus document on the use of percutaneous left ventricular assist support devices during complex high-risk indicated PCI. <i>International Journal of Cardiology</i> , 2019, 293, 84-90.	1.7	46
66	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	2.9	12
67	Risk of contrast-induced nephropathy in patients undergoing complex percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019, 290, 59-63.	1.7	23
68	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007133.	3.9	17
69	Daily risk of adverse outcomes in patients undergoing complex lesions revascularization: A subgroup analysis from the RAIN-CARDIOGROUP VII study (veRy thin stents for patients with left main or Tj ETQq1 1 0.784314 rgBT / Overlock 10	1.7	17
70	Long-term follow-up of covered stent implantation for various coronary artery diseases. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 571-577.	1.7	17
71	Impact of Final Kissing Balloon and of Imaging on Patients Treated on Unprotected Left Main Coronary Artery With Thin-Strut Stents (From the RAIN-CARDIOGROUP VII Study). <i>American Journal of Cardiology</i> , 2019, 123, 1610-1619.	1.6	20
72	Impact of Discharge Location After Transcatheter Aortic Valve Replacement on 1-Year Outcomes in Women: Results From the WIN-TAVI Registry. <i>Canadian Journal of Cardiology</i> , 2019, 35, 199-207.	1.7	7

#	ARTICLE	IF	CITATIONS
73	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. <i>Thrombosis and Haemostasis</i> , 2019, 119, 149-162.	3.4	107
74	Are we ready for a gender-specific approach in interventional cardiology?. <i>International Journal of Cardiology</i> , 2019, 286, 226-233.	1.7	28
75	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	2.2	7
76	New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-comers, international, multicenter DELTA-2 registry. <i>International Journal of Cardiology</i> , 2019, 280, 30-37.	1.7	4
77	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. <i>Clinical Research in Cardiology</i> , 2019, 108, 643-650.	3.3	21
78	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.	1.6	9
79	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019, 283, 78-83.	1.7	33
80	Residual angina in female patients after coronary revascularization. <i>International Journal of Cardiology</i> , 2019, 286, 208-213.	1.7	6
81	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1124-1131.	1.7	22
82	Self-expandable sirolimus-eluting stents compared to second-generation drug-eluting stents for the treatment of the left main: A propensity score analysis from the SPARTA and the FAILSAFE registries. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 208-215.	1.7	1
83	Sex and Transcatheter Aortic Valve Implantation: Impact of Female Sex on Clinical Outcomes. <i>Interventional Cardiology Review</i> , 2019, 14, 137-141.	1.6	7
84	Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. <i>International Journal of Cardiology</i> , 2018, 250, 66-72.	1.7	33
85	Mid-term clinical outcomes after bailout drug-eluting stenting for suboptimal drug-coated balloon results: Insights from a Milan registry. <i>International Journal of Cardiology</i> , 2018, 263, 17-23.	1.7	14
86	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. <i>International Journal of Cardiology</i> , 2018, 263, 24-28.	1.7	6
87	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	2.9	28
88	1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1-12.	2.9	77
89	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	2.9	22
90	Incidence and outcomes of emergent cardiac surgery during transfemoral transcatheter aortic valve implantation (TAVI): insights from the European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI). <i>European Heart Journal</i> , 2018, 39, 676-684.	2.2	91

#	ARTICLE	IF	CITATIONS
91	Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina. JACC: Cardiovascular Interventions, 2018, 11, 784-792.	2.9	42
92	Computed tomography predictors of mortality, stroke and conduction disturbances in women undergoing TAVR: A sub-analysis of the WIN-TAVI registry. Journal of Cardiovascular Computed Tomography, 2018, 12, 338-343.	1.3	25
93	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	3.9	24
94	A comparison of the fully repositionable and retrievable Boston Lotus and direct flow medical valves for the treatment of severe aortic stenosis: A single center experience. Catheterization and Cardiovascular Interventions, 2018, 91, 966-974.	1.7	3
95	Provisional versus elective two-stent strategy for unprotected true left main bifurcation lesions: Insights from a FAILS-2 sub-study. International Journal of Cardiology, 2018, 250, 80-85.	1.7	14
96	Definite stent thrombosis after drug-eluting stent implantation in coronary bifurcation lesions: A meta-analysis of 3,107 patients from 14 randomized trials. Catheterization and Cardiovascular Interventions, 2018, 92, 680-691.	1.7	9
97	New-Generation Drug-Eluting Stents for Left Main In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 2438-2440.	2.9	3
98	A Practical Approach to the Management of Complications During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 1797-1810.	2.9	64
99	What the surgeon needs to know about percutaneous coronary intervention treatment of chronic total occlusions. Annals of Cardiothoracic Surgery, 2018, 7, 533-545.	1.7	2
100	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). American Journal of Cardiology, 2018, 122, 1909-1916.	1.6	18
101	Predictors of Advanced Conduction Disturbances Requiring a Late (>48 H) Permanent Pacemaker Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 1519-1526.	2.9	77
102	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
103	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	1.6	19
104	Percutaneous coronary intervention for the left main stem and other bifurcation lesions: 12th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 13, 1540-1553.	3.2	185
105	Percutaneous coronary and structural interventions in women: a position statement from the EAPCI Women Committee. EuroIntervention, 2018, 14, e1227-e1235.	3.2	13
106	Percutaneous coronary intervention in left main coronary artery disease: the 13th consensus document from the European Bifurcation Club. EuroIntervention, 2018, 14, 112-120.	3.2	94
107	Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 119, 1088-1093.	1.6	36
108	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11,473 patients. European Heart Journal, 2017, 38, ehw627.	2.2	138

#	ARTICLE	IF	CITATIONS
109	The Unforgettable Cornerstone. Journal of the American College of Cardiology, 2017, 69, 755-756.	2.8	0
110	Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Second-Generation Drug-Eluting Stents (from Failure in Left Main Study With 2nd Generation) Tj ETQq0 0 0 rgBT /Overlock 108Tf 50 697	2.8	108
111	The ratio of contrast volume to glomerular filtration rate predicts acute kidney injury and mortality after transcatheter aortic valve implantation. Cardiovascular Revascularization Medicine, 2017, 18, 349-355.	0.8	13
112	Does pre-existing aortic regurgitation protect from death in patients who develop paravalvular leak after TAVI?. International Journal of Cardiology, 2017, 233, 52-60.	1.7	18
113	Transcatheter Aortic Valve Implantation in Patients With Advanced Chronic Kidney Disease. American Journal of Cardiology, 2017, 119, 1438-1442.	1.6	29
114	Platelet reactivity in response to loading dose of atorvastatin or rosuvastatin in patients with stable coronary disease before percutaneous coronary intervention: The <scp>STATIPLAT</scp> randomized study. Clinical Cardiology, 2017, 40, 605-611.	1.8	9
115	Radial Versus Femoral Access for the Treatment of Left Main Lesion in the Era of Second-Generation Drug-Eluting Stents. American Journal of Cardiology, 2017, 120, 33-39.	1.6	12
116	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology, 2017, 69, 2011-2022.	2.8	109
117	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	1.7	11
118	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
119	Bioresorbable Vascular Scaffolds and Very Late Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 745-746.	2.9	2
120	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 645-654.	2.9	17
121	Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients – results from the BELLO (balloon elution and late loss) Tj ETQq1 1 0.784314 rgBT /Overlock 108Tf 50 697	2.8	108
122	Impact of Mitral Annular Calcium on Outcomes after Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2017, 120, 2233-2240.	1.6	22
123	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	32
124	First Experience With the Coronary Sinus Reducer System for the Management of Refractory Angina in Patients Without Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1901-1903.	2.9	33
125	Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions. International Journal of Cardiology, 2017, 246, 26-31.	1.7	7
126	Dual Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1471-1472.	2.9	1

#	ARTICLE	IF	CITATIONS
127	Prognostic Significance of Change in the Left Ventricular Ejection Fraction After Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis and Left Ventricular Dysfunction. American Journal of Cardiology, 2017, 120, 1639-1647.	1.6	12
128	Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102,735 patients. European Heart Journal, 2017, 38, 3160-3172.	2.2	66
129	Transapical aortic valve replacement is a safe option in patients with poor left ventricular ejection fraction: results from the Italian Transcatheter Balloon-Expandable Registry (ITER). European Journal of Cardio-thoracic Surgery, 2017, 52, 874-880.	1.4	9
130	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	6.1	25
131	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Tj ETQq1 1 0.784314 rgBT /Over 2017, 120, 904-910.	1.6	10
132	Five-year evolution of mild aortic regurgitation following transcatheter aortic valve implantation: early insights from a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 75-82.	1.1	5
133	Analysis of a Low Dose Protocol to Reduce Patient Radiation Exposure During Percutaneous Coronary Interventions. American Journal of Cardiology, 2017, 119, 203-209.	1.6	12
134	Short-term versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled analysis of six randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 178-189.	1.7	18
135	Long-term outcomes following mini-crush versus culotte stenting for the treatment of unprotected left main disease: Insights from the milan and New-Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2017, 89, 13-24.	1.7	11
136	Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound. Catheterization and Cardiovascular Interventions, 2017, 89, 789-797.	1.7	5
137	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	1.7	13
138	The DELTA 2 Registry. JACC: Cardiovascular Interventions, 2017, 10, 2401-2410.	2.9	41
139	Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy. EuroIntervention, 2017, 12, 1730-1737.	3.2	58
140	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	2.9	54
141	Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Catheterization and Cardiovascular Interventions, 2016, 88, 522-528.	1.7	15
142	A Bicuspid Aortic Valve Imaging Classification for the TAVR Era. JACC: Cardiovascular Imaging, 2016, 9, 1145-1158.	5.3	174
143	Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds. Catheterization and Cardiovascular Interventions, 2016, 88, 854-862.	1.7	8
144	Percutaneous treatment of left main disease: Still learning about the optimal PCI strategy. Cardiovascular Revascularization Medicine, 2016, 17, 494-496.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2016, 117, 1714-1723.	1.6	57
146	Clinical outcomes following bioresorbable scaffold implantation in small vessels. <i>International Journal of Cardiology</i> , 2016, 207, 59-61.	1.7	2
147	Bioresorbable Scaffolds for the Management of Coronary Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 989-1000.	2.9	16
148	Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women. <i>Coronary Artery Disease</i> , 2016, 27, 442-448.	0.7	9
149	A challenging case of transcatheter aortic prosthesis dysfunction: Endocarditis or thrombosis?. <i>International Journal of Cardiology</i> , 2016, 214, 500-501.	1.7	1
150	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	2.9	51
151	Long-Term (≥10 Years) Safety of Percutaneous Treatment of Unprotected Left Main Stenosis With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2016, 118, 32-39.	1.6	20
152	Transcatheter aortic valve implantation in intermediate- and low-risk populations: An inevitable progression?. <i>International Journal of Cardiology</i> , 2016, 210, 35-37.	1.7	7
153	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	2.8	445
154	Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2016, 118, 107-112.	1.6	38
155	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1851-1864.	2.8	319
156	T-Stenting With Small Protrusion. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1853-1854.	2.9	4
157	Impact of Angiographic Result After Predilatation on Outcome After Drug-Coated Balloon Treatment of In-Stent Coronary Restenosis. <i>American Journal of Cardiology</i> , 2016, 118, 1460-1465.	1.6	34
158	Impact of gender on long-term mortality in patients with unprotected left main disease: The Milan and New-Tokyo (MITO) Registry. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 369-374.	0.8	19
159	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	20
160	Impact of post-procedural hyperglycemia on acute kidney injury after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2016, 221, 892-897.	1.7	12
161	Acute and 30-Day Outcomes in Women After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1589-1600.	2.9	85
162	Resource utilization for transfemoral transcatheter aortic valve replacement: An international comparison. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 145-151.	1.7	2

#	ARTICLE	IF	CITATIONS
163	The EBC TWO Study (European Bifurcation Coronary TWO). Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	102
164	Incidence and significance of side branch occlusions following bioresorbable scaffold implantation for long left anterior descending artery lesions. International Journal of Cardiology, 2016, 222, 674-675.	1.7	1
165	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
166	Early and mid-term outcomes of 1904 patients undergoing transcatheter balloon-expandable valve implantation in Italy: results from the Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER). European Journal of Cardio-thoracic Surgery, 2016, 50, 1139-1148.	1.4	32
167	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
168	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	2.9	37
169	Predictive ability of the CHADS ₂ and CHA ₂ DS ₂ -VASc scores for stroke after transcatheter aortic balloon-expandable valve implantation: an Italian Transcatheter Balloon-Expandable Valve Implantation Registry (ITER) sub-analysis. European Journal of Cardio-thoracic Surgery, 2016, 50, 867-873.	1.4	11
170	Comparison Between 1- and 2-Stent Strategies in Unprotected Distal Left Main Disease. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	19
171	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ, The, 2016, 354, i4935.	6.0	43
172	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ, The, 2016, 355, i5483.	6.0	48
173	Clinical outcomes following target lesion revascularization for bioresorbable scaffold failure. Catheterization and Cardiovascular Interventions, 2016, 87, 832-836.	1.7	6
174	Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation. Catheterization and Cardiovascular Interventions, 2016, 88, 865-870.	1.7	5
175	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
176	Transarterial Endoleak Closure After Endovascular Thoracoabdominal Aneurysm Repair. Journal of Endovascular Therapy, 2016, 23, 220-224.	1.5	0
177	Left Main Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 125-134.	0.4	1
178	Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: The SECURITY (Second-Generation Drug-Eluting Stent) Trial. International Journal of Cardiology, 2016, 207, 168-176.	1.7	22
179	Provisional vs. two-stent technique for unprotected left main coronary artery disease after ten years follow up: A propensity matched analysis. International Journal of Cardiology, 2016, 211, 37-42.	1.7	48
180	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	3.9	12

#	ARTICLE	IF	CITATIONS
181	Long-Term Outcomes After Transcatheter Aortic Valve Implantation from a Single High-Volume Center (The Milan Experience). American Journal of Cardiology, 2016, 117, 813-819.	1.6	16
182	Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-Rotterdam-Milano-Toulouse In Collaboration Aortic Stenosis survey. EuroIntervention, 2016, 11, e1305-e1313.	3.2	15
183	Percutaneous coronary intervention for coronary bifurcation disease: 11th consensus document from the European Bifurcation Club. EuroIntervention, 2016, 12, 38-46.	3.2	181
184	The European Bifurcation Club Left Main Study (EBC MAIN): rationale and design of an international, multicentre, randomised comparison of two stent strategies for the treatment of left main coronary bifurcation disease. EuroIntervention, 2016, 12, 47-52.	3.2	37
185	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. EuroIntervention, 2016, 12, e623-e631.	3.2	17
186	Impact of permanent pacemaker on mortality after transcatheter aortic valve implantation: the PRAGMATIC (Pooled Rotterdam-Milan-Toulouse in Collaboration) Pacemaker substudy. EuroIntervention, 2016, 12, 1185-1193.	3.2	38
187	Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations. EuroIntervention, 2016, 11, 989-995.	3.2	19
188	Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds. EuroIntervention, 2016, 11, 1355-1362.	3.2	23
189	Bifurcations: Tips and Tricks. , 2016, , 215-219.		0
190	Bioresorbable scaffolds for the treatment of complex lesions: are we there yet?. Interventional Cardiology, 2015, 7, 35-54.	0.0	2
191	First generation versus new generation drug-eluting stents for the treatment of ostial/midshaft lesions in unprotected left main coronary artery: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2015, 85, E63-9.	1.7	8
192	Impact of Mixed Aortic Valve Stenosis on <sc>VARC</sc>â€2 Outcomes and Postprocedural Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation. Catheterization and Cardiovascular Interventions, 2015, 86, 875-885.	1.7	27
193	Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheterization and Cardiovascular Interventions, 2015, 85, E10-E15.	1.7	53
194	Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: Overall outcomes and comparison between provisional and planned double stenting strategy. Catheterization and Cardiovascular Interventions, 2015, 86, 644-652.	1.7	25
195	Early Outcomes With Direct Flow Medical Versus Firstâ€Generation Transcatheter Aortic Valve Devices: A Singleâ€Center Propensityâ€Matched Analysis. Journal of Interventional Cardiology, 2015, 28, 583-593.	1.2	10
196	Dual antiplatelet therapy following drug-eluting stent implantation: how long is long enough?. Expert Review of Cardiovascular Therapy, 2015, 13, 585-587.	1.5	2
197	Impact of Strut Width in Periprocedural Myocardial Infarction. JACC: Cardiovascular Interventions, 2015, 8, 900-909.	2.9	44
198	Reply. Journal of the American College of Cardiology, 2015, 65, 2360-2361.	2.8	0

#	ARTICLE	IF	CITATIONS
199	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 75 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	1.6	32
200	Feasibility of ultra-low contrast 64-slice computed tomography angiography before transcatheter aortic valve implantation: a real-world experience. European Heart Journal Cardiovascular Imaging, 2015, 17, 175.	1.2	17
201	Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002025.	3.9	80
202	Influence of baseline ejection fraction on the prognostic value of paravalvular leak after transcatheter aortic valve implantation. International Journal of Cardiology, 2015, 190, 277-281.	1.7	12
203	Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	1.6	28
204	Impact and natural history of postprocedural aortic regurgitation on early and midterm mortality following transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis. Journal of Cardiovascular Medicine, 2015, 16, 286-295.	1.5	2
205	Drug-Coated Balloons Versus Second-Generation Drug-Eluting Stents for the Management of Recurrent Multimetall-Layered In-Stent Restenosis. JACC: Cardiovascular Interventions, 2015, 8, 1586-1594.	2.9	43
206	Is There Still a Survival Advantage to Bypass Surgery Over Percutaneous Intervention in the Modern Era?. Progress in Cardiovascular Diseases, 2015, 58, 335-341.	3.1	4
207	Left Main Stem Disease. , 2015, , 2205-2217.		0
208	Technical Aspects of Left Main Stem Percutaneous Coronary Intervention. , 2015, , 237-253.		0
209	How long should dual antiplatelet therapy be continued following implantation of drug eluting stents?. Annals of Translational Medicine, 2015, 3, S10.	1.7	0
210	Drug-eluting stent outcomes in diabetes. Expert Review of Cardiovascular Therapy, 2014, 12, 95-109.	1.5	10
211	PlaCor PRT measurement of shear-activated platelet aggregate formation in stable patients treated with single and dual antiplatelet therapy. Platelets, 2014, 25, 337-342.	2.3	1
212	Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: The Milan-New Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 83, 530-538.	1.7	16
213	Optimal Medical Treatment: Is It the Worst Option in Multivessel Coronary Disease? Response. Revista Espanola De Cardiologia (English Ed), 2014, 67, 1075.	0.6	0
214	Tratamiento mÃ©dico Ã³ptimo: Â¿es la peor opciÃ³n en la enfermedad coronaria multivaso? Respuesta. Revista Espanola De Cardiologia, 2014, 67, 1075.	1.2	0
215	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 75	1.6	32
216	One Versus Two Stents. JACC: Cardiovascular Interventions, 2014, 7, 264-265.	2.9	1

#	ARTICLE	IF	CITATIONS
217	Elección de intervención coronaria percutánea o bypass en la enfermedad coronaria multivaso. Revista Española De Cardiología, 2014, 67, 428-431.	1.2	5
218	Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. Annals of Thoracic Surgery, 2014, 97, 22-28.	1.3	64
219	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. JACC: Cardiovascular Interventions, 2014, 7, 354-361.	2.9	45
220	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf Cardiology, 2014, 113, 1348-1355.	1.8	14
221	The impact of main branch restenosis on long term mortality following drug-eluting stent implantation in patients with <i>de novo</i> unprotected distal left main bifurcation coronary lesions: The Milan and Newâ€Tokyo (MITO) registry. Catheterization and Cardiovascular Interventions, 2014, 84, 341-348.	1.7	18
222	Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations. Catheterization and Cardiovascular Interventions, 2014, 83, 889-895.	1.7	8
223	Dual Antiplatelet Therapy after Drug-Eluting Stents â€” How Long to Treat?. New England Journal of Medicine, 2014, 371, 2225-2226.	27.0	18
224	One-year outcome of biolimus eluting stent with biodegradable polymer in all comers: The Italian Nobori Stent Prospective Registry. International Journal of Cardiology, 2014, 177, 11-16.	1.7	8
225	Tardive Coronary Obstruction By a Native Leaflet After Transcatheter Aortic Valve Replacement in a Patient With Heavily Calcified Aortic Valve Stenosis. JACC: Cardiovascular Interventions, 2014, 7, e105-e107.	2.9	6
226	Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2014, 64, 2086-2097.	2.8	388
227	A comparison of the femoral and radial crossover techniques for vascular access management in transcatheter aortic valve implantation: The milan experience. Catheterization and Cardiovascular Interventions, 2014, 83, 156-161.	1.7	30
228	Usefulness of Baseline Activated Clotting Timeâ€“Guided Heparin Administration in Reducing Bleeding Events During Transfemoral Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2014, 7, 140-151.	2.9	20
229	Impact of renal dysfunction on long-term mortality in patients with unprotected left main disease: Milan and New-Tokyo (MITO) Registry. International Journal of Cardiology, 2014, 177, 1131-1133.	1.7	6
230	Drug-Eluting Balloon in the Treatment of Inâ€Stent Restenosis and Diffuse Coronary Artery Disease: Realâ€World Experience from Our Registry. Journal of Interventional Cardiology, 2014, 27, 348-355.	1.2	20
231	The role of intravascular ultrasound and quantitative angiography in the functional assessment of intermediate coronary lesions: Correlation with fractional flow reserve. Cardiovascular Revascularization Medicine, 2014, 15, 3-7.	0.8	19
232	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Severely Stenotic Bicuspid Versus Tricuspid or Nonbicuspid Valves. American Journal of Cardiology, 2014, 113, 1390-1393.	1.6	79
233	Red blood cell distribution width predicts one-year mortality following transcatheter aortic valve implantation. International Journal of Cardiology, 2014, 172, 456-457.	1.7	12
234	Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European Bifurcation Club meetings. EuroIntervention, 2014, 10, 545-560.	3.2	213

#	ARTICLE	IF	CITATIONS
235	Drug-eluting stent implantation in patients with acute coronary syndrome - the Activity of Platelets after Inhibition and Cardiovascular Events: Optical Coherence Tomography (APICE OCT) study. EuroIntervention, 2014, 10, 916-923.	3.2	9
236	Left Main Stem Disease. , 2014, , 1-16.		1
237	Aspirin intolerance and the need for dual antiplatelet therapy after stent implantation: A proposed alternative regimen. International Journal of Cardiology, 2013, 165, 444-447.	1.7	27
238	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet, The, 2013, 382, 1714-1722.	13.7	537
239	Managing Patients With an Indication for Anticoagulant Therapy After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 111, 237-242.	1.6	18
240	Resultados a muy largo plazo tras la implantación de stents liberadores de fármacos en la estenosis de arteria coronaria principal izquierda no protegida: experiencia de un centro. Revista Espanola De Cardiologia, 2013, 66, 24-33.	1.2	10
241	The Role of Drug-Eluting Balloons Alone or in Combination With Drug-Eluting Stents in the Treatment of De Novo Diffuse Coronary Disease. JACC: Cardiovascular Interventions, 2013, 6, 1153-1159.	2.9	41
242	Predictors of cardiac death in patients with coronary chronic total occlusion not revascularized by PCI. International Journal of Cardiology, 2013, 168, 1402-1409.	1.7	73
243	First- versus second-generation drug-eluting stents for the treatment of coronary bifurcations. Cardiovascular Revascularization Medicine, 2013, 14, 311-315.	0.8	21
244	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery. JACC: Cardiovascular Interventions, 2013, 6, 1242-1249.	2.9	75
245	A New Tool to Manage Side-Branch Occlusion After Covered-Stent Implantation for Vascular Complications. JACC: Cardiovascular Interventions, 2013, 6, 893-894.	2.9	3
246	Diabetes and everolimus-eluting stents: what we know and what is still missing. Insights from subanalysis of the SORT OUT IV trial. Expert Review of Cardiovascular Therapy, 2013, 11, 151-154.	1.5	0
247	Very Long-term Outcomes Following Drug-eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis: A Single Center Experience. Revista Espanola De Cardiologia (English Ed), 2013, 66, 24-33.	0.6	3
248	Comparison of First- and Second-Generation Drug-Eluting Stents in Saphenous Vein Grafts Used as Aorto-Coronary Conduits. American Journal of Cardiology, 2013, 112, 318-322.	1.6	20
249	Heyde's Syndrome Incidence and Outcome in Patients Undergoing Transcatheter Aortic Valve Implantation. Journal of the American College of Cardiology, 2013, 61, 687-689.	2.8	73
250	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet, The, 2013, 382, 1879-1888.	13.7	127
251	Clinical outcome and quality of life in octogenarians following transcatheter aortic valve implantation (TAVI) for symptomatic aortic stenosis. International Journal of Cardiology, 2013, 168, 281-286.	1.7	24
252	Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices. Journal of the American College of Cardiology, 2013, 61, 830-836.	2.8	176

#	ARTICLE	IF	CITATIONS
253	Discrepancies in vessel sizing between angiography and intravascular ultrasound varies according to the vessel evaluated. International Journal of Cardiology, 2013, 168, 3791-3796.	1.7	9
254	Trends in outcome after transfemoral transcatheter aortic valve implantation. American Heart Journal, 2013, 165, 183-192.	2.7	49
255	Effect of Body Mass Index on Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2013, 111, 231-236.	1.6	58
256	Acute Stent Recoil From Aggressive Post-Dilation of a Second-Generation Drug-Eluting Stent. JACC: Cardiovascular Interventions, 2013, 6, 311-313.	2.9	7
257	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet, The, 2013, 381, 639-650.	13.7	679
258	Comparison of Incidence and Predictors of Left Bundle Branch Block After Transcatheter Aortic Valve Implantation Using the CoreValve Versus the Edwards Valve. American Journal of Cardiology, 2013, 112, 554-559.	1.6	118
259	Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: A Pooled-Rotterdam-Milano-Toulouse In Collaboration Plus (PRAGMATIC-Plus) initiative substudy. American Heart Journal, 2013, 165, 752-760.	2.7	77
260	Single-stent crossover technique from distal unprotected left main coronary artery to the left circumflex artery. Catheterization and Cardiovascular Interventions, 2013, 82, 757-764.	1.7	12
261	The Long-Term Clinical Outcome of T-Stenting and Small Protrusion Technique for Coronary Bifurcation Lesions. JACC: Cardiovascular Interventions, 2013, 6, 554-561.	2.9	22
262	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. American Heart Journal, 2013, 165, 65-72.	2.7	212
263	Impact of Mean Platelet Volume on Combined Safety Endpoint and Vascular and Bleeding Complications following Percutaneous Transcatheter Aortic Valve Implantation. BioMed Research International, 2013, 2013, 1-8.	1.9	14
264	Impact of Residual Chronic Total Occlusion of Right Coronary Artery on the Long-term Outcome in Patients Treated for Unprotected Left Main Disease. Circulation: Cardiovascular Interventions, 2013, 6, 154-160.	3.9	24
265	A "modified crossover technique" for vascular access management in high-risk patients undergoing transfemoral transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2013, 81, 579-583.	1.7	30
266	"Procedural trauma risks longitudinal shortening of the promus element," stent platform. Catheterization and Cardiovascular Interventions, 2013, 81, 810-817.	1.7	17
267	Consensus from the 7th European Bifurcation Club meeting. EuroIntervention, 2013, 9, 36-45.	3.2	102
268	Two-year outcomes following unprotected left main stenting with first vs. new-generation drug-eluting stents: the FINE registry. EuroIntervention, 2013, 9, 809-816.	3.2	26
269	How should I treat a left main spontaneous dissection involving left anterior descending artery, intermediate branch artery and left circumflex artery?. EuroIntervention, 2013, 9, 285-289.	3.2	0
270	Coronary artery bypass graft versus percutaneous coronary intervention with drug-eluting stent implantation for diabetic patients with unprotected left main coronary artery disease: the D-DELTA registry. EuroIntervention, 2013, 9, 803-808.	3.2	2

#	ARTICLE	IF	CITATIONS
271	Current management of left main coronary artery disease. European Heart Journal, 2012, 33, 36-50.	2.2	100
272	Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem. Circulation: Cardiovascular Interventions, 2012, 5, 491-498.	3.9	29
273	Percutaneous valve replacement in a young adult for radiation-induced aortic stenosis. Journal of Cardiovascular Medicine, 2012, 13, 397-398.	1.5	14
274	Adverse impact of bleeding and transfusion on the outcome post-transcatheter aortic valve implantation: Insights from the Pooled-Rotterdam-Milano-Toulouse In Collaboration Plus (PRAGMATIC) Tj ETQq0 0.7gBT /Over 10 T	0.7	10
275	Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: A propensity scoreâ€“matched case-control study. American Heart Journal, 2012, 164, 910-917.	2.7	111
276	Incidence of Overall Bleeding in Patients Treated With Intra-Aortic Balloon Pump During Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 350-357.	2.9	21
277	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
278	Stent Thrombosis After Kissing Balloons. JACC: Cardiovascular Interventions, 2012, 5, 1290-1291.	2.9	0
279	Incidence, Management, and Outcomes of Cardiac Tamponade During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Interventions, 2012, 5, 1264-1272.	2.9	91
280	Incidence, Predictors, and Implications of Access Site Complications With Transfemoral Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2012, 110, 1361-1367.	1.6	210
281	Left Main Thrombotic Occlusion Following Balloon Aortic Valvuloplasty for Severe Aortic Stenosis. Canadian Journal of Cardiology, 2012, 28, 759.e13-759.e15.	1.7	6
282	Stent Thrombosis: Incidence, Predictors and New Technologies. Thrombosis, 2012, 2012, 1-12.	1.4	53
283	Coronary chronic total occlusions. Catheterization and Cardiovascular Interventions, 2012, 79, 20-27.	1.7	71
284	Pericardium-covered stent: a reality for coronary interventions of the future?. Interventional Cardiology, 2012, 4, 411-418.	0.0	2
285	Transcatheter valve-in-valve implantation with the Edwards SAPIEN in patients with bioprosthetic heart valve failure: the Milan experience. EuroIntervention, 2012, 7, 1275-1284.	3.2	43
286	Quality of life improvement is maintained up to two years after transcatheter aortic valve implantation in high-risk surgical candidates. EuroIntervention, 2012, 8, 429-436.	3.2	21
287	The occupational effects of interventional cardiology: results from the WIN for Safety survey. EuroIntervention, 2012, 8, 658-663.	3.2	57
288	ACS and STEMI treatment: gender-related issues. EuroIntervention, 2012, 8, P27-P35.	3.2	19

#	ARTICLE	IF	CITATIONS
289	Successful Percutaneous Anterograde Transcatheter Valve-in-Valve Implantation in the Mitral Position. JACC: Cardiovascular Interventions, 2011, 4, 1246-1247.	2.9	25
290	SCAI Consensus Document on Occupational Radiation Exposure to the Pregnant Cardiologist and Technical Personnel. Heart Lung and Circulation, 2011, 20, 83-90.	0.4	12
291	Comparison of Long-Term Clinical and Angiographic Outcomes Following Implantation of Bare Metal Stents and Drug-Eluting Stents in Aorto-Ostial Lesions. American Journal of Cardiology, 2011, 108, 1055-1060.	1.6	19
292	Long-term follow-up of multivessel percutaneous coronary intervention with drug-eluting stents for de novo lesions with correlation to the SYNTAX score. Cardiovascular Revascularization Medicine, 2011, 12, 220-227.	0.8	10
293	Long-Term Outcomes After the Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions, 2011, 4, 155-164.	2.9	66
294	Periprocedural and Short-Term Outcomes of Transfemoral Transcatheter Aortic Valve Implantation With the Sapien XT as Compared With the Edwards Sapien Valve. JACC: Cardiovascular Interventions, 2011, 4, 743-750.	2.9	62
295	SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. Catheterization and Cardiovascular Interventions, 2011, 77, 232-241.	1.7	62
296	Predictors of moderate-to-severe paravalvular aortic regurgitation immediately after corevalve implantation and the impact of postdilatation. Catheterization and Cardiovascular Interventions, 2011, 78, 432-443.	1.7	125
297	Incidence, Predictors, Management, Immediate and Long-Term Outcomes Following Grade III Coronary Perforation. JACC: Cardiovascular Interventions, 2011, 4, 87-95.	2.9	170
298	Recognition and management of complications during transcatheter aortic valve implantation. Expert Review of Cardiovascular Therapy, 2011, 9, 913-926.	1.5	18
299	SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. EuroIntervention, 2011, 6, 866-874.	3.2	37
300	Treatment of iatrogenic occlusive coronary dissections: a novel approach. EuroIntervention, 2011, 7, 106-111.	3.2	16
301	Crosser As First choice for crossing Totally occluded coronary arteries (CRAFT Registry): focus on conventional angiography and computed tomography angiography predictors of success. EuroIntervention, 2011, 7, 480-486.	3.2	11
302	The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN ³ and Medtronic CoreValve ReValving System [®] devices: the Milan registry. EuroIntervention, 2011, 7, 556-563.	3.2	80
303	Percutaneous Unprotected Left Main Coronary Artery Interventions – Updated Results and Current Recommendations. Interventional Cardiology Review, 2011, 6, 44.	1.6	0
304	Tools & Techniques: Left main coronary artery percutaneous coronary intervention. EuroIntervention, 2011, 6, 1020-1021.	3.2	1
305	Percutaneous Transcatheter Aortic Valve Implantation. Cardiology in Review, 2010, 18, 111-124.	1.4	21
306	5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions. JACC: Cardiovascular Interventions, 2010, 3, 595-601.	2.9	136

#	ARTICLE	IF	CITATIONS
307	Outcomes After Transcatheter Aortic Valve Implantation With Both Edwards-SAPIEN and CoreValve Devices in a Single Center. JACC: Cardiovascular Interventions, 2010, 3, 1110-1121.	2.9	124
308	Prolonged Double Antiplatelet Therapy in a Cohort of "De Novo" Diabetic Patients Treated With Drug-Eluting Stent Implantation. American Journal of Cardiology, 2010, 105, 1395-1401.	1.6	6
309	Clinical and Angiographic Outcomes After Percutaneous Recanalization of Chronic Total Saphenous Vein Graft Occlusion Using Modern Techniques. American Journal of Cardiology, 2010, 106, 1721-1727.	1.6	45
310	Gender-based issues in interventional cardiology: A consensus statement from the Women in Innovations (WIN) Initiative. Catheterization and Cardiovascular Interventions, 2010, 75, 145-152.	1.7	17
311	Clinical Outcomes Following Protected Carotid Artery Stenting in Symptomatic and Asymptomatic Patients. Journal of Endovascular Therapy, 2010, 17, 298-307.	1.5	9
312	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. Circulation: Cardiovascular Interventions, 2010, 3, 249-256.	3.9	17
313	Renal function and drug-eluting stent. International Journal of Cardiology, 2010, 142, 92-94.	1.7	9
314	Cuestiones relativas al sexo en cardiología intervencionista: declaración de consenso de la iniciativa Women in Innovations (WIN). Revista Espanola De Cardiologia, 2010, 63, 200-208.	1.2	7
315	Elective Double Stenting for Left Main Coronary Artery Bifurcation Lesions. , 2010, , 149-192.		3
316	Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative. EuroIntervention, 2010, 5, 773-779.	3.2	21
317	Long-term follow-up (four years) of unprotected left main coronary artery disease treated with paclitaxel-eluting stents (from the TRUE Registry). EuroIntervention, 2010, 5, 906-916.	3.2	14
318	Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic Plaques. Journal of Immunology, 2009, 183, 2537-2544.	0.8	27
319	Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures. Circulation: Cardiovascular Interventions, 2009, 2, 416-422.	3.9	54
320	Impact of optimal medical therapy and percutaneous coronary intervention on patients with stable angina. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 92-93.	3.3	0
321	Histopathology of Clinical Coronary Restenosis in Drug-Eluting Versus Bare Metal Stents. American Journal of Cardiology, 2009, 104, 1660-1667.	1.6	54
322	Multicenter international registry of unprotected left main coronary artery percutaneous coronary intervention with drug-eluting stents in patients with myocardial infarction. Catheterization and Cardiovascular Interventions, 2009, 73, 15-21.	1.7	37
323	Evaluation of intermediate coronary stenosis with intravascular ultrasound and fractional flow reserve: Its use and abuse. Catheterization and Cardiovascular Interventions, 2009, 73, 441-448.	1.7	30
324	Rebuttal: Response to Dr. Morton Kern. Catheterization and Cardiovascular Interventions, 2009, 74, 814-814.	1.7	0

#	ARTICLE	IF	CITATIONS
325	Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?. Thrombosis Journal, 2009, 7, 4.	2.1	45
326	Clinical Outcomes After Unrestricted Implantation of Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2009, 2, 1219-1226.	2.9	28
327	Incidence and Management of Restenosis After Treatment of Unprotected Left Main Disease With Drug-Eluting Stents. Journal of the American College of Cardiology, 2009, 54, 1131-1136.	2.8	50
328	Novel Approaches for Preventing or Limiting Events (Naples) II Trial. Journal of the American College of Cardiology, 2009, 54, 2157-2163.	2.8	223
329	Rotational atherectomy followed by drug-eluting stent implantation in calcified coronary lesions. EuroIntervention, 2009, 5, 370-374.	3.2	78
330	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Stent Implantation in Patients Taking Chronic Oral Anticoagulation. JACC: Cardiovascular Interventions, 2008, 1, 56-61.	2.9	85
331	Clinical and Angiographic Follow-Up of Small Vessel Lesions Treated With Paclitaxel-Eluting Stents (from the TRUE Registry). American Journal of Cardiology, 2008, 102, 1002-1008.	1.6	33
332	Incidence of Bleeding and Compliance on Prolonged Dual Antiplatelet Therapy (Aspirin +) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 Td (1477-1481.	1.6	23
333	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 51, 2212-2219.	2.8	160
334	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. European Heart Journal, 2008, 29, 2108-2115.	2.2	99
335	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. American Heart Journal, 2008, 155, 274-283.	2.7	170
336	Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. American Heart Journal, 2008, 156, 745-750.	2.7	25
337	Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The Diabetes and Drug Eluting stent for LeFT main registry (D-DELFT). EuroIntervention, 2008, 4, 77-83.	3.2	9
338	Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery. Circulation, 2007, 116, 158-162.	1.6	182
339	Drug-Eluting Stent Update 2007. Circulation, 2007, 116, 1424-1432.	1.6	56
340	Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment. Circulation, 2007, 116, 745-754.	1.6	430
341	Repeated drug-eluting stent implantation for drug-eluting stent restenosis: The same or a different stent. American Heart Journal, 2007, 153, 354-359.	2.7	79
342	Comparable Clinical Outcomes With Paclitaxel- and Sirolimus-Eluting Stents in Unrestricted Contemporary Practice. Journal of the American College of Cardiology, 2007, 49, 2320-2328.	2.8	48

#	ARTICLE	IF	CITATIONS
343	Angiographic Analysis of Pattern of Late Luminal Loss in Sirolimus- and Paclitaxel-Eluting Stents. American Journal of Cardiology, 2007, 99, 593-598.	1.6	19
344	Frequency of Slow Coronary Flow Following Successful Stent Implantation and Effect of Nitroprusside. American Journal of Cardiology, 2007, 99, 916-920.	1.6	26
345	Late Restenosis Following Sirolimus-Eluting Stent Implantation. American Journal of Cardiology, 2007, 100, 41-44.	1.6	60
346	Drug-eluting stents: What is the balance of risks and benefits?. Current Cardiovascular Risk Reports, 2007, 1, 279-283.	2.0	0
347	Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. Vascular Health and Risk Management, 2007, 3, 441-51.	2.3	8
348	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush" Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	2.8	228
349	Drug-Eluting Stent Restenosis. Journal of the American College of Cardiology, 2006, 47, 2399-2404.	2.8	92
350	Elective versus provisional intraaortic balloon pumping in unprotected left main stenting. American Heart Journal, 2006, 152, 565-572.	2.7	69
351	Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: Insights from the TRUE (Taxus in Real-life Usage Evaluation) Study. International Journal of Cardiology, 2006, 108, 406-407.	1.7	22
352	Early Outcome of Treatment of Ostial De Novo Left Anterior Descending Coronary Artery Lesions With Drug-Eluting Stents. American Journal of Cardiology, 2006, 97, 187-191.	1.6	25
353	Comparison of Sirolimus Versus Paclitaxel Eluting Stents for Treatment of Coronary In-Stent Restenosis. American Journal of Cardiology, 2006, 97, 1182-1187.	1.6	24
354	Progression Rate of Ascending Aortic Dilation in Patients With Normally Functioning Bicuspid and Tricuspid Aortic Valves. American Journal of Cardiology, 2006, 98, 249-253.	1.6	72
355	Impact of Sirolimus-Eluting and Paclitaxel-Eluting Stents on Outcome in Patients With Diabetes Mellitus and Stenting in More Than One Coronary Artery. American Journal of Cardiology, 2006, 98, 362-366.	1.6	43
356	Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheterization and Cardiovascular Interventions, 2006, 67, 175-180.	1.7	88
357	A novel approach to chronic total occlusions: The crosser system. Catheterization and Cardiovascular Interventions, 2006, 68, 29-35.	1.7	54
358	Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. European Heart Journal, 2006, 27, 540-546.	2.2	89
359	Response to Letters Regarding Article, "Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis: A Single-Center Experience". Circulation, 2006, 114, .	1.6	5
360	Percutaneous Treatment With Drug-Eluting Stent Implantation Versus Bypass Surgery for Unprotected Left Main Stenosis. Circulation, 2006, 113, 2542-2547.	1.6	287

#	ARTICLE	IF	CITATIONS
361	Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 396-400.	3.3	16
362	Treatment of saphenous vein graft lesions with drug-eluting stents. <i>Journal of the American College of Cardiology</i> , 2005, 45, 989-994.	2.8	142
363	In-hospital and nine-month outcome of treatment of coronary bifurcational lesions with sirolimus-eluting stent. <i>American Journal of Cardiology</i> , 2005, 95, 757-760.	1.6	59
364	Validation of Predictors of Intraprocedural Stent Thrombosis in the Drug-Eluting Stent Era. <i>American Journal of Cardiology</i> , 2005, 95, 1466-1468.	1.6	40
365	17-Beta-Estradiol Eluting Stent Versus Phosphorylcholine-Coated Stent for the Treatment of Native Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2005, 96, 664-667.	1.6	25
366	Clinical Outcome Following Aleatory Implantation of Paclitaxel-Eluting or Sirolimus-Eluting Stents in Complex Coronary Lesions. <i>American Journal of Cardiology</i> , 2005, 96, 1663-1668.	1.6	42
367	Preliminary experience with the frontrunner coronary catheter: Novel device dedicated to mechanical revascularization of chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 146-152.	1.7	40
368	Is overdilatation of 3.0 mm sirolimus-eluting stent associated with a higher restenosis rate?. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 129-133.	1.7	13
369	Treating chronic total occlusions using subintimal tracking and reentry: The STAR Technique. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 64, 407-411.	1.7	243
370	Early and Mid-Term Results of Drug-Eluting Stent Implantation in Unprotected Left Main. <i>Circulation</i> , 2005, 111, 791-795.	1.6	358
371	Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2126.	7.4	2,769
372	Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. <i>European Heart Journal</i> , 2005, 26, 1056-1062.	2.2	133
373	Sirolimus-eluting stent implantation in diabetic patients with multivessel coronary artery disease. <i>American Heart Journal</i> , 2005, 150, 807-813.	2.7	18
374	Angiographic patterns of restenosis after paclitaxel-eluting stent implantation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 805-806.	2.8	36
375	Multiple Overlapping Drug-Eluting Stents to Treat Diffuse Disease of the Left Anterior Descending Coronary Artery. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1570-1573.	2.8	103
376	Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique. <i>Journal of the American College of Cardiology</i> , 2005, 46, 613-620.	2.8	320
377	Safety and feasibility of Bivalirudin with either Cypher and Taxus drug-eluting stent during percutaneous coronary intervention. <i>EuroIntervention</i> , 2005, 1, 70-4.	3.2	3
378	Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents. <i>Circulation</i> , 2004, 109, 2732-2736.	1.6	88

#	ARTICLE	IF	CITATIONS
379	Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. American Journal of Cardiology, 2004, 93, 213-216.	1.6	103
380	Creatine kinase-myocardial band isoenzyme elevation after percutaneous coronary interventions using sirolimus-eluting stents. American Journal of Cardiology, 2004, 93, 1397-1401.	1.6	10
381	Effectiveness of sirolimus-eluting stent implantation for treatment of in-stent restenosis after brachytherapy failure. American Journal of Cardiology, 2004, 94, 351-354.	1.6	18
382	Comparison of clinical and angiographic outcome of sirolimus-eluting stent implantation versus cutting balloon angioplasty for coronary in-stent restenosis. American Journal of Cardiology, 2004, 94, 1297-1300.	1.6	20
383	Polymer-Based Paclitaxel-Eluting Coronary Stents. Herz, 2004, 29, 147-151.	1.1	18
384	Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. Journal of the American College of Cardiology, 2004, 43, 1154-1160.	2.8	88
385	Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. Journal of the American College of Cardiology, 2004, 44, 967-971.	2.8	97
386	Beta-radiation therapy for long lesions in native coronary vessels. Cardiovascular Radiation Medicine, 2003, 4, 18-24.	0.6	2
387	Modified T-stenting technique with crushing for bifurcation lesions: Immediate results and 30-day outcome. Catheterization and Cardiovascular Interventions, 2003, 60, 145-151.	1.7	237
388	Initial experience with a new 8 French-compatible directional atherectomy catheter: Immediate and mid-term results. Catheterization and Cardiovascular Interventions, 2003, 60, 159-166.	1.7	5
389	Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent Implantation. Circulation, 2003, 107, 2178-2180.	1.6	168
390	First Clinical Experience With a Paclitaxel Derivateâ€“Eluting Polymer Stent System Implantation for In-Stent Restenosis. Circulation, 2002, 105, 1883-1886.	1.6	188
391	Results and Long-Term Predictors of Adverse Clinical Events After Elective Percutaneous Interventions on Unprotected Left Main Coronary Artery. Circulation, 2002, 106, 698-702.	1.6	199
392	In-stent restenosis in small coronary arteries. Journal of the American College of Cardiology, 2002, 40, 403-409.	2.8	244
393	Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Isletâ€“Transplanted Rats. Circulation, 2001, 103, 2980-2986.	1.6	104
394	Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. Journal of the American College of Cardiology, 2000, 35, 214-221.	2.8	129